Guangmin Li

发表

Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug Conjugates.

Yanli Wang, J. Wai, Donglu Zhang, 2017, Bioconjugate chemistry.

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Juthamas Sukbuntherng, Robert A Blake, Guangmin Li, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

John M Lambert, Wai Lee T Wong, Guangmin Li, 2008, Cancer research.

The cryptophycins as potent payloads for antibody drug conjugates.

S. Spencer, Vishal A. Verma, G. Phillips, 2015, Bioorganic & medicinal chemistry letters.

Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.

M. Sliwkowski, R. Scheller, S. Spencer, 2014, Journal of medicinal chemistry.

Clinical Cancer esearch cer Therapy : Preclinical ineered Thio-Trastuzumab-DM 1 Conjugate with an roved Therapeutic Index to Target Human Epidermal R wth Factor Receptor 2 – Positive Breast Cancer

S. Spencer, P. Polakis, K. Parsons, 2010 .

Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513.

E. Plise, L. Salphati, Guangmin Li, 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug Conjugates.

R. Rowntree, James Lee, D. Stokoe, 2018, Molecular pharmaceutics.

Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers.

Jeffrey T. Lau, BinQing Wei, S. Spencer, 2017, Journal of medicinal chemistry.

Development, Optimization, and Structural Characterization of an Efficient Peptide-Based Photoaffinity Cross-Linking Reaction for Generation of Homogeneous Conjugates from Wild-Type Antibodies.

Peter S Liu, W. Sandoval, M. Ultsch, 2018, Bioconjugate chemistry.

A homogeneous high-DAR antibody–drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides

R. Rowntree, A. Kamath, D. Reilly, 2021, Chemical science.

Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.

A. Ebens, R. Kelley, M. Junttila, 2014, Cancer research.

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells

M. Sliwkowski, Jun Guo, G. Phillips, 2018, Molecular Cancer Therapeutics.

Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

M. Sliwkowski, F. André, N. Harbeck, 2013, Clinical Cancer Research.

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

M. Sliwkowski, G. Phillips, Guangmin Li, 2011, Breast Cancer Research and Treatment.

Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells.

J. Cherrington, D. Mendel, Guangmin Li, 2003, Molecular cancer therapeutics.

SU6668 inhibits Flk‐1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice

J. Cherrington, J. Christensen, D. Mendel, 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Clinical Cancer esearch cer Therapy : Preclinical ineered Thio-Trastuzumab-DM 1 Conjugate with an roved Therapeutic Index to Target Human Epidermal R wth Factor Receptor 2 – Positive Breast Cancer

M. Sliwkowski, R. Scheller, S. Spencer, 2010 .

Attachment Site Cysteine Thiol pKa Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody-Drug Conjugates.

G. A. Lazar, Genee Y. Lee, B. Vollmar, 2017, Bioconjugate chemistry.

Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity.

S. Steinbacher, BinQing Wei, C. Eigenbrot, 2017, Journal of medicinal chemistry.

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

O. Potapova, J. Cherrington, Angela Barone, 2006, Molecular Cancer Therapeutics.

JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell.

Jie Liu, Huan Wang, J. Saavedra, 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Systematic Variation of Pyrrolobenzodiazepine (PBD)-dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody-Drug Conjugates.

R. Rowntree, BinQing Wei, P. Dragovich, 2020, Journal of medicinal chemistry.

Cytotoxic Drug Conjugate − Trastuzumab-DM 1 , an Antibody Targeting HER 2-Positive Breast Cancer with Updated

M. Sliwkowski, H. Koeppen, R. Lutz, 2008 .

The cryptophycins as potent payloads for antibody drug conjugates.

S. Spencer, Vishal A. Verma, G. Phillips, 2015, Bioorganic & medicinal chemistry letters.

Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

M. Sliwkowski, S. Spencer, P. Polakis, 2010, Clinical Cancer Research.

Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.

A. Ebens, R. Kelley, M. Junttila, 2014, Cancer research.

223 Trastuzumab-DM1: mechanisms of action and mechanisms of resistance

G. Phillips, Guangmin Li, Carter Fields, 2010 .

Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug Conjugates.

Yanli Wang, J. Wai, Donglu Zhang, 2017, Bioconjugate chemistry.